AGENUS INC
AGENUS INC (AGEN): 12 pipeline candidates · 4 upcoming catalysts · ~4 mo cash runway · 13 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
4.4 months
0% dilution
Lead: Approved
12 candidates
4 upcoming, next in ~697d
N/A
A transparent, data-derived signal for AGENUS INCacross cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$123.3M
Cash
$35.0M
Quarterly Burn
$36.0M
Runway
4.4 mo
Revenue
$33.7M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (12 candidates)
| Drug | Phase |
|---|---|
| agen1884 | Phase 2 |
| agen2034 | Phase 2 |
| agen2373 | Phase 2 |
| balstililmab | Phase 2 |
| Balstilimab | Phase 1 |
| Botensilimab | Phase 1 |
| FLOT | Phase 3 |
| Folfox Protocol | Phase 3 |
| hydrocodone bi | Approved |
| potassium | Approved |
Showing 10 of 12 candidates. Sign up for full pipeline.
Upcoming Catalysts (4)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
86
Total value held
$32.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,880,464 | $9.6M |
| vanguard portfolio management llc | 1,195,109 | $4.0M |
| marshall wace, llp | 688,203 | $2.3M |
| blackrock, inc. | 545,662 | $1.8M |
| geode capital management, llc | 348,395 | $1.2M |
| morgan stanley | 295,821 | $988K |
| renaissance technologies llc | 285,646 | $954K |
| man group plc | 278,980 | $932K |
| walleye capital llc | 241,130 | $805K |
| raymond james financial inc | 239,554 | $800K |
Showing top 10 of 86 institutional holders of AGENUS INC. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in AGENUS INC's pipeline?
AGENUS INC (AGEN) has 12 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AGENUS INC's lead drug candidate?
AGENUS INC's most advanced tracked candidate is agen1884 (Phase 2) for Cervical Cancer.
What is AGENUS INC's next catalyst?
AGENUS INC's next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: A Multicenter, Randomised, Comparative, Open-label Phase III Aiming to Compare the Survival of Patie" — expected May 15, 2028.
What is AGENUS INC's cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AGENUS INC has approximately 4.4 months of cash runway.
What is AGENUS INC's market capitalization?
AGENUS INC's market capitalization is approximately $123.3M.
Get the full picture on AGENUS INC
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.